A Test in Focus

This new gene panel cancer test helps tailor therapies to the individual patient based on the unique genomic signature of the patient’s tumor. This test scans specific regions in 50 genes known to affect tumor growth and response to therapies. The test is now available to Mayo Clinic patients and to providers worldwide through Mayo Medical Laboratories.

By Andy Tofilon • April 24, 2014

This new Mayo Clinic assay provides clinicians an accurate measurement of serum thyroglobulin in patients with known or suspected anti-thyroglobulin autoantibodies or heterophilic antibodies. View a quick overview of the test’s details and a five-minute video interview with Dr. Stefan Grebe.

By Kelley Luedke • April 8, 2014

This new Mayo Clinic assay detects the 14 high-risk HPV types, and if present, provides specific genotype results for HPV-16 and/or HPV-18.

By Andy Tofilon • February 11, 2014

Dr. Robin Patel, Division Chair of Clinical Microbiology, answers questions about Mayo Clinic’s new KPC and NDM Surveillance PCR test.

By Andy Tofilon • January 24, 2014

David Murray, M.D., Ph.D., provides a brief overview of the new Alpha-1-Antitrypsin Proteotype S/Z by LC-MS/MS, Serum test now available from Mayo Medical Laboratories. This test should be ordered for individuals suspected of A1A deficiency and can be used for diagnosis and identification of a specific proteotype to determine prognosis.

By Andy Tofilon • December 19, 2013

Robin Patel, M.D., chair of Mayo Clinic’s Division of Microbiology, provides a three-minute overview of a new test for Coxiella burnetii, the causative agent of Q fever. The real-time PCR test rapidly detects Coxiella burnetii DNA in clinical specimens by targeting a sequence of the shikimate dehydrogenase gene (aroE) unique to Coxiella burnetii.

By Andy Tofilon • November 13, 2013

Melanocytic tumors arising in the skin can present a significant diagnostic challenge. While many lesions can be easily classified as benign nevi or malignant melanoma based on histologic features alone, there is a significant subset of lesions that cannot be clearly defined as either benign or malignant. To aid in diagnosis and differentiation of malignant from benign melanocytic lesions, a (FISH)-based test panel has been developed.

By Andy Tofilon • September 26, 2013